Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

被引：3
|
作者：
Freedland, Stephen J. [1 ]
Sandin, Rickard [2 ]
Sah, Janvi [3 ]
Emir, Birol [4 ]
Mu, Qiao [3 ]
Ratiu, Anna [3 ]
Hong, Agnes [5 ]
Serfass, Lucile [6 ]
Tagawa, Scott T. [7 ]
机构：
[1] Vet Affairs Hlth Care Syst, Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA USA
[2] Pfizer AB, Sollentuna, Sweden
[3] STATinMED Res, Ann Arbor, MI USA
[4] Pfizer Inc, New York, NY USA
[5] Astellas Pharma Inc, Northbrook, IL USA
[6] Pfizer Inc, Paris, France
[7] New York Presbyterian Hosp, Weill Cornell Med Div Hematol & Med Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).
    Du, Shawn
    Pilon, Dominic
    Khilfeh, Ibrahim
    Muser, Erik
    Rossi, Carmine
    Kinkead, Frederic
    Diaz, Lilian
    Korsiak, Jill
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 51 - 51
  • [22] Multidisciplinary real-world management of metastatic castration-sensitive prostate cancer: A French national study (PROFILE study)
    Helissey, Carole
    Maillet, Denis
    Narciso, Berengere
    Berdah, Jean-Francois
    Ouzaid, Idir
    Hilgers, Werner
    Fiard, Gaelle
    Duberge, Thomas
    Jovenin, Nicolas
    Topart, Delphine
    Beauval, Jean -Baptiste
    Bergeron, Mathias
    Roubaud, Guilhem
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (7-8):
  • [23] Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel
    Shintaro Narita
    Takahiro Kimura
    Shingo Hatakeyama
    Kenichi Hata
    Takafumi Yanagisawa
    Shinya Maita
    Shuji Chiba
    Hiromi Sato
    Soki Kashima
    Atsushi Koizumi
    Ryohei Yamamoto
    Koichiro Takayama
    Katsumi Okane
    Toshiya Ishida
    Yohei Horikawa
    Teruaki Kumazawa
    Jiro Shimoda
    Takehiro Suzuki
    Chikara Ohyama
    Shin Egawa
    Tomonori Habuchi
    International Journal of Clinical Oncology, 2022, 27 : 1477 - 1486
  • [24] Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel
    Narita, Shintaro
    Kimura, Takahiro
    Hatakeyama, Shingo
    Hata, Kenichi
    Yanagisawa, Takafumi
    Maita, Shinya
    Chiba, Shuji
    Sato, Hiromi
    Kashima, Soki
    Koizumi, Atsushi
    Yamamoto, Ryohei
    Takayama, Koichiro
    Okane, Katsumi
    Ishida, Toshiya
    Horikawa, Yohei
    Kumazawa, Teruaki
    Shimoda, Jiro
    Suzuki, Takehiro
    Ohyama, Chikara
    Egawa, Shin
    Habuchi, Tomonori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (09) : 1477 - 1486
  • [25] Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
    Kaye, Deborah R.
    Khilfeh, Ibrahim
    Muser, Erik
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Pilon, Dominic
    George, Daniel
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 381 - 391
  • [26] RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
    Mark, Michael
    von Moos, Roger
    Cathomas, Richard
    Stoffel, Sandro
    Gillessen, Silke
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (04): : 635 - 636
  • [27] Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
    Mitchell, Aaron P.
    Mishra, Akriti
    Panageas, Katherine S.
    Lipitz-Snyderman, Allison
    Bach, Peter B.
    Morris, Michael J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 419 - 426
  • [28] Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).
    Barata, Pedro C.
    Montgomery, Rachel
    Last, Matthew
    Gillespie-Akar, Liane
    Nazari, Jonathan
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States EDITORIAL COMMENT
    Swami, Umang
    Agarwal, Neeraj
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1429 - 1429
  • [30] Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
    Chung, B. H.
    Huang, J.
    Uemura, H.
    Choi, Y. D.
    Ye, Z.
    Suzuki, H.
    Kang, T. W.
    He, D.
    Joung, J. Y.
    Brookman-May, S. D.
    McCarthy, S.
    Bhaumik, A.
    He, J.
    Mundle, S. D.
    Chowdhury, S.
    Agarwal, N.
    Ye, D.
    Chi, K. N.
    Uemura, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S649 - S650
12345